Resistance trends of Bacteroides fragilis group over an 8-Year Period, 1997-2004, in Korea

Korean Journal of Laboratory Medicine

Volumn 29, Issue 4, 2009, Pages 293-298

  Roh, Kyoung Ho ^a   Kim, Sinyoung ^b   Kim, Chang Ki ^c   Yum, Jong Hwa ^d   Kim, Myung Sook ^b   Yong, Dongeun ^b   Lee, Kyungwon ^b   Kim, June Myung ^b   Chong, Yunsop ^b  

^a Korea University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c Korean Institute of Tuberculosis   (South Korea)

^d Dong Eui University   (South Korea)

Author keywords

Antimicrobial susceptibility; Bacteroides fragilis group; Korea; Trend

Indexed keywords

ANTIINFECTIVE AGENT; CEFOXITIN; CHLORAMPHENICOL; DRUG DERIVATIVE; IMIPENEM; METRONIDAZOLE; PENICILLANIC ACID; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM;

ARTICLE; BACTEROIDES; BACTEROIDES FRAGILIS; CLASSIFICATION; DRUG EFFECT; HUMAN; ISOLATION AND PURIFICATION; MICROBIOLOGICAL EXAMINATION; MULTIDRUG RESISTANCE; SOUTH KOREA;

ANTI-BACTERIAL AGENTS; BACTEROIDES; BACTEROIDES FRAGILIS; CEFOXITIN; CHLORAMPHENICOL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; IMIPENEM; METRONIDAZOLE; MICROBIAL SENSITIVITY TESTS; PENICILLANIC ACID; PIPERACILLIN; REPUBLIC OF KOREA;

EID: 73349102191     PISSN: 15986535     EISSN: None     Source Type: Journal    
DOI: 10.3343/kjlm.2009.29.4.293     Document Type: Article

References (28)

1. Citron DM, Poxton IR, Baron EJ. Bacteroides, Porphyromonas, Prevotella, Fusobacterium, and other anaerobic gram-negative rods. In: Murray PR, Baron EJ, et al, eds. Manual of Clinical Microbiology. 9th ed. Washington D.C.: ASM Press, 2007:911-32.
2. Goldstein EJ. Anaerobic bacteremia. Clin Infect Dis 1996;23(S1):S97-101.
3. Lassmann B, Gustafson DR, Wood CM, Rosenblatt JE. Reemergence of anaerobic bacteremia. Clin Infect Dis 2007;44:895-900.
4. Redondo MC, Arbo MD, Grindlinger J, Snydman DR. Attributable mortality of bacteremia associated with the Bacteroides fragilis group. Clin Infect Dis 1995;20:1492-6.
5. Behra-Miellet J, Calvet L, Mory F, Muller C, Chomarat M, Bezian MC, et al. Antibiotic resistance among anaerobic Gram-negative bacilli: lessons from a French multicentric survey. Anaerobe 2003; 9:105-11.
6. Snydman DR, Jacobus NV, McDermott LA, Ruthazer R, Golan Y, Goldstein EJ, et al. National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004. Antimicrob Agents Chemother 2007;51:1649-55.
7. Nguyen MH, Yu VL, Morris AJ, McDermott L, Wagener MW, Harrell L, et al. Antimicrobial resistance and clinical outcome of Bacteroides bacteremia: findings of a multicenter prospective observational trial. Clin Infect Dis 2000;30:870-6.
8. Lee K, Chong Y, Jeong SH, Xu XS, Kwon OH. Emerging resistance of anaerobic bacteria to antimicrobial agents in South Korea. Clin Infect Dis 1996;23(S1):S73-7.
9. Lee K, Shin HB, Chong Y. Antimicrobial resistance patterns of Bacteroides fragilis group organisms in Korea. Yonsei Med J 1998;39: 578-86.
10. Clinical Laboratory Standards Institute. Methods for antimicrobial susceptibility testing of anaerobic bacteria; approved standards. M11-A6. 6th ed. Wayne, PA: Clinical Laboratory Standards Institute, 2004.
11. Snydman DR, Jacobus NV, McDermott LA, Ruthazer R, Goldstein EJ, Finegold SM, et al. National survey on the susceptibility of Bacteroides Fragilis Group: report and analysis of trends for 1997-2000. Clin Infect Dis 2002;35(S1):S126-34.
12. Holdeman LV, Cato EP, et al. eds. Anaerobic laboratory manual. 4th ed. Blacksburg, VA: Virginia Polytechnic Institute and State University, 1977.
13. Summanen P, Baron EJ, et al. eds. Wadsworth anaerobic bacteriology manual. 5th ed. Belmont, CA: Star Publishing, 1993.
14. Goldstein EJ and Snydman DR. Intra-abdominal infections: review of the bacteriology, antimicrobial susceptibility and the role of ertapenem in their therapy. J Antimicrob Chemother 2004;53(S2):ii29-36.
15. Soki J, Edwards R, Hedberg M, Fang H, Nagy E, Nord CE. Examination of cfiA-mediated carbapenem resistance in Bacteroides fragilis strains from a European antibiotic susceptibility survey. Int J Antimicrob Agents 2006;28:497-502.
16. Betriu C, Culebras E, Gomez M, Lopez F, Rodriguez-Avial I, Picazo JJ. Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain. Antimicrob Agents Chemother 2008;52:2686-90.
17. Snydman DR, Jacobus NV, McDermott LA. In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. Antimicrob Agents Chemother 2008;52:4492-6.
18. Podglajen I, Breuil J, Casin I, Collatz E. Genotypic identification of two groups within the species Bacteroides fragilis by ribotyping and by analysis of PCR-generated fragment patterns and insertion sequence content. J Bacteriol 1995;177:5270-5.
19. Khushi T, Payne DJ, Fosberry A, Reading C. Production of metal dependent beta-lactamases by clinical strains of Bacteroides fragilis isolated before 1987. J Antimicrob Chemother 1996;37:345-50.
20. Walsh TR, Onken A, Haldorsen B, Toleman MA, Sundsfjord A. Characterization of a carbapenemase-producing clinical isolate of Bacteroides fragilis in Scandinavia: genetic analysis of a unique insertion sequence. Scand J Infect Dis 2005;37:676-9.
21. Rasmussen BA, Bush K, Tally FP. Antimicrobial resistance in Bacteroides. Clin Infect Dis 1993;16(S4):S390-400.
22. Stearne LE, van Boxtel D, Lemmens N, Goessens WH, Mouton JW, Gyssens IC. Comparative study of the effects of ceftizoxime, piperacillin, and piperacillin-tazobactam concentrations on antibacterial activity and selection of antibiotic-resistant mutants of Enterobacter cloacae and Bacteroides fragilis in vitro and in vivo in mixed-infection abscesses. Antimicrob Agents Chemother 2004;48:1688-98.
23. Lee K, Jang IH, Kim YJ, Chong Y. In vitro susceptibilities of the Bacteroides fragilis group to 14 antimicrobial agents in Korea. Antimicrob Agents Chemother 1992;36:195-7.
24. Liu CY, Huang YT, Liao CH, Yen LC, Lin HY, Hsueh PR. Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. Antimicrob Agents Chemother 2008;52:3161-8.
25. Rasmussen BA, Bush K, Tally FP. Antimicrobial resistance in anaerobes. Clin Infect Dis 1997;24(S1):S110-20.
26. Brazier JS, Stubbs SL, Duerden BI. Metronidazole resistance among clinical isolates belonging to the Bacteroides fragilis group: time to be concerned? J Antimicrob Chemother 1999;44:580-1.
27. Dubreuil L, Breuil J, Dublanchet A, Sedallian A. Survey of the susceptibility patterns of Bacteroides fragilis group strains in France from 1977 to 1992. Eur J Clin Microbiol Infect Dis 1992;11:1094-9.
28. Suata K, Watanabe K, Ueno K, Homma M. Antimicrobial susceptibility patterns and resistance transferability among Bacteroides fragilis group isolates from patients with appendicitis in Bali, Indonesia. Clin Infect Dis 1993;16:561-6.